Home > Dermatology > AAD 2022 > New Developments and Unmet Needs in Dermatology > JAK inhibitors: A risk assessment

JAK inhibitors: A risk assessment

Presented By
Prof. Brett King, Yale School of Medicine, USA
AAD 2022
Janus kinase (JAK) inhibitors have entered the arena in dermatology and show efficacy in numerous indications. Recently, the drug class got a black box warning from the American FDA. A decision that was criticised by experts during the 2022 AAD Annual Meeting. “JAK inhibitors are changing the landscape of what we do in dermatology,” explained Prof. Brett King (Yale School of Medicine, CT, USA) [1]. Besides corticosteroids, no drug class is used in so many indications. Recently, the FDA issued a black box warning for JAK inhibitors. These warnings appear printed on the package insert of the drug surrounded by a black border (hence the name). By doing so, the FDA wants to alert consumers about the serious or life-threatening side effects the drug might have. As Prof. King pointed out, commonly reported adverse events with JAK inhibitors are upper respiratory tract infections, headache, nasopharyngitis, nausea, and acne. The black box warning refers to seriou...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on